Mesoblast Limited (NASDAQ:MESO) and CTI BioPharma Corp. (NASDAQ:CTIC) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast Limited	16.28M	25.15	86.07M	-0.90	0.00
CTI BioPharma Corp.	12.28M	5.01	44.51M	-0.87	0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Mesoblast Limited and CTI BioPharma Corp.

Profitability

Table 2 represents Mesoblast Limited (NASDAQ:MESO) and CTI BioPharma Corp. (NASDAQ:CTIC)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast Limited	-528.69%	-16%	-12.5%
CTI BioPharma Corp.	-362.46%	-77.4%	-49.1%

Volatility and Risk

Mesoblast Limited has a beta of 1.76 and its 76.00% more volatile than S&P 500. Competitively, CTI BioPharma Corp.’s beta is 1.59 which is 59.00% more volatile than S&P 500.

Liquidity

The current Quick Ratio of Mesoblast Limited is 2.9 while its Current Ratio is 2.9. Meanwhile, CTI BioPharma Corp. has a Current Ratio of 3.6 while its Quick Ratio is 3.6. CTI BioPharma Corp. is better positioned to pay off its short-term and long-term debts than Mesoblast Limited.

Institutional and Insider Ownership

Mesoblast Limited and CTI BioPharma Corp. has shares owned by institutional investors as follows: 2.8% and 61.1%. Competitively, CTI BioPharma Corp. has 0.1% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Mesoblast Limited	-5.75%	-3.4%	-11.8%	-28.76%	-43.28%	3.4%
CTI BioPharma Corp.	21.23%	0%	-30.41%	-36.02%	-70.32%	62.21%

For the past year Mesoblast Limited was less bullish than CTI BioPharma Corp.

Summary

On 6 of the 10 factors CTI BioPharma Corp. beats Mesoblast Limited.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.